Cosmos Health’s Cana Laboratories Boosts Manufacturing Capabilities and Secures Major Contract
Chicago, IL – April 9, 2025 – In an exciting development, Cosmos Health Inc. (NASDAQ: COSM), a leading global healthcare group, announced that its subsidiary, Cana Laboratories (“Cana”), has recently completed significant upgrades to its manufacturing facilities. These enhancements have increased Cana’s capacity to produce a broader range of healthcare products, including the antiseptic drug, AMBITASOL 1L.
Expanded Manufacturing Capabilities
The upgrades to Cana’s manufacturing capabilities have resulted in a more efficient and versatile production process. This not only enables Cana to meet the growing demand for its proprietary pharmaceutical and nutraceutical brands but also allows the company to take on contract manufacturing projects for other pharmaceutical companies.
Long-Term Partnership with Pharmex S.A.
Building on this success, Cana has secured a five-year contract manufacturing agreement with Pharmex S.A. (“Pharmex”), a renowned international pharmaceutical company. Under the terms of this agreement, Cana will produce 300,000 bottles of AMBITASOL 1L annually, totaling 1,500,000 units over the contract’s duration.
Impact on Consumers
For consumers, this partnership represents a commitment to delivering high-quality healthcare products on a larger scale. With Cana’s expanded manufacturing capabilities and the security of a long-term contract, consumers can expect a consistent supply of AMBITASOL 1L, ensuring they have access to this essential antiseptic drug when they need it.
- Greater availability of AMBITASOL 1L
- Continuous supply of high-quality antiseptic drug
- Boost to consumer confidence in Cosmos Health and Cana Laboratories
Impact on the World
Beyond the immediate benefits for consumers, this partnership between Cosmos Health and Pharmex S.A. has broader implications for the healthcare industry and the world at large. By increasing production capacity for essential pharmaceuticals, companies like Cosmos Health and Cana Laboratories can help address global health challenges, particularly in emerging markets where access to healthcare products remains limited.
- Increased production capacity for essential pharmaceuticals
- Addressing global health challenges and improving access to healthcare in underserved areas
- Contribution to the growth and development of the healthcare industry
Conclusion
The recent upgrades to Cana Laboratories’ manufacturing capabilities and the securing of a long-term contract manufacturing agreement with Pharmex S.A. mark a significant milestone in Cosmos Health’s growth story. This partnership not only strengthens Cosmos Health’s position as a leading healthcare group but also contributes to the global effort to address healthcare challenges and improve access to essential pharmaceuticals. For consumers, this development means greater availability and reliability of high-quality healthcare products, ensuring they can maintain their health and well-being. Together, Cosmos Health and Cana Laboratories are paving the way for a healthier, more connected world.
Stay tuned for more updates on Cosmos Health and its subsidiaries as they continue to innovate and drive positive change in the healthcare industry.
